Myelodysplastic syndromeDiagnosisBlastsRing sideroblastsMolecular diagnosticsObjectives: Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms that are often difficult to diagnose due to their pathologic and clinical heterogeneity. The key features of MDS are peripheral blood cytopenias, ineffective...
Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. 喜欢 0 阅读量: 20 DOI: 10.1200/JCO.2010.31.6265 被引量: 3 年份: 2011 收藏 引用 批量引用 报错 分享 全部来源 求助全文 dx.doi.org ...
Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 2009; 144:451-2.Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW. Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 2009;144:451-452....
CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplactics Syndromes (MDS) CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplactics Syndromes (MDS)Stroke associated with antiphospholipid syndrome ... R Siguenza,MH Banas,I ...
Myelodysplastic syndromes (MDS) are categorized into different risk groups according to the International Prognostic Scoring System (IPSS). Patients with low- and intermediate-1-risk disease are usually qualified as low-risk-MDS and treated with common treatment strategies. Recently, a number of new ...
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood, 108 (2006), pp. 1037-1044 CrossrefView in ScopusGoogle Scholar 26 D Hodzic, C Kong, MJ Wainszelbaum, AJ Charron, X Su, PD Stahl TBC1D3, a hominoid oncoprotein, is encoded...
Described is the therapy-related AML (acute myelogenetic leukemia)/MDS (myelo-dysplasia syndrome), which is manifested after various treatments of low-grade B-cell lymphoma and has strongly attracted attention because of the markedly improved prognosis due to recent advantages of the therapy for the...
Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.
Su YW, Chang MC, Chiang MF et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 2005;71:315–318.
None of the patients with grade II and III acute GVHD died from this complication; 9% of evaluable patients died with grade IV acute GVHD. While this value appeared lower than previously reported after conventional HCT, improved GVHD control remains a critical future research objective. Chronic ...